Neurostimulation Rewires Your Brain to Silence Chronic Pain for Good

Neurostimulation for chronic pain management basically rewires how your brain perceives pain by sending gentle electrical pulses to specific nerves. Instead of masking the sensation, it interrupts pain signals before they reach your brain, offering a real alternative for when medications fall short. You can adjust the settings to match your comfort level, making it a personalized tool you control.

Understanding Electrical Modulation of Pain Pathways

Understanding electrical modulation of pain pathways means recognizing that neurostimulation, like spinal cord or peripheral nerve stimulation, works by overriding faulty pain signals. These devices deliver precise electrical pulses that interrupt or dampen pain transmission along the spinal cord before it reaches the brain. You adjust amplitude or frequency to target specific pathways, often creating a tingling sensation that replaces the perception of pain. This paresthesia isn’t always necessary for relief, as newer sub-perception settings can work without you feeling the stimulation at all. The key is finding the right stimulation parameters for your unique nerve circuit, which directly determines how effectively neurostimulation brings chronic pain under control.

How Targeted Nerve Stimulation Interrupts Pain Signals

Targeted nerve stimulation interrupts pain signals by delivering precisely calibrated electrical pulses that block or override nociceptive transmission along afferent pathways. This technique directly disrupts the propagation of action potentials in A-delta and C fibers, preventing pain signals from reaching the central nervous system. By stimulating large-diameter myelinated fibers, such as A-beta, it activates inhibitory interneurons in the spinal cord’s substantia gelatinosa, effectively closing the “gate” to ascending pain input. This nociceptive signal interruption also modulates sodium channel kinetics, raising the depolarization threshold required for pain impulse generation. The result is a sustained, reversible blockade that replaces pathological pain signaling with controlled paresthesia or subthreshold activity.

Key Differences Between Peripheral and Central Nervous System Targets

The key split between peripheral and central nervous system targets comes down to where you’re interrupting the pain signal. Peripheral nerve stimulation (PNS), like a spinal cord stimulator lead placed on a dorsal root ganglion, acts as a gatekeeper at the source—it blocks nociceptive input before it even reaches the spinal cord. In contrast, central targets, such as the periaqueductal gray or motor cortex, modulate descending pathways or alter how the brain processes that signal centrally. This difference in real estate leads to a clear sequence in application:

1. Target selection hinges on pain origin: PNS for focal, neuropathic limb pain; central for diffuse or failed-back-surgery pain.
2. Programming differs—peripheral leads require lower frequencies to avoid motor activation, while central targets often need higher frequencies for cortical engagement.

The Scientific Rationale Behind Using Current to Calm Nerves

The scientific rationale behind using current to calm nerves hinges on the gate control theory of pain. Electrical stimulation preferentially activates large-diameter, non-painful Aβ nerve fibers. These fibers transmit signals faster than pain-carrying Aδ and C fibers, effectively “closing the gate” in the spinal cord’s substantia gelatinosa. This blocks ascending pain signals from reaching the brain. Simultaneously, the applied current can modulate voltage-gated sodium channels, raising the neuron’s firing threshold and reducing ectopic discharges from damaged nerves. This hyperpolarization effectively dampens nerve excitability, stabilizing hyperactive neural circuits that drive chronic pain.

• Selectively activates Aβ fibers to inhibit pain signal transmission in the spinal dorsal horn.
• Modulates voltage-gated sodium channels to raise the nerve’s activation threshold.
• Reduces ectopic discharges by hyperpolarizing the nerve membrane potential.

Major Device Categories and Their Clinical Applications

For chronic pain management, the two major device categories are spinal cord stimulators (SCS) and dorsal root ganglion (DRG) stimulators. SCS systems, delivering paresthesia or sub-perception waveforms over the dorsal columns, are clinically applied for failed back surgery syndrome and neuropathic limb pain, often requiring trial leads to confirm coverage. DRG stimulators target specific focal pain, such as complex regional pain syndrome or post-herpetic neuralgia, by precisely modulating the DRG within the spinal canal. Which device category typically offers more focal relief for localized pain conditions? DRG stimulators, as they directly address the dermatomal source of neuropathic pain with fewer off-target effects, making them the preferred clinical choice for discrete, regional chronic pain syndromes.

Spinal Cord Stimulators for Back and Limb Discomfort

Spinal cord stimulation directly addresses chronic back and limb discomfort by delivering mild electrical pulses to the dorsal column of the spinal cord via implanted leads. This modulation disrupts pain signals ascending to the brain, offering an alternative for patients unresponsive to conservative therapies. Clinically, leads are placed percutaneously or surgically in the epidural space, targeting specific dermatomal levels corresponding to the patient’s pain distribution. A programmable pulse generator, implanted subcutaneously, allows voltage and frequency adjustments to optimize paresthesia coverage over the affected limbs or lower back. Therapy is typically trialed for several days to confirm efficacy before permanent implantation.

• Requires careful lead placement to overlap paresthesia with the patient’s pain pattern
• Common for failed back surgery syndrome and complex regional pain syndrome
• Programmable parameters enable real-time adaptation to activity levels or positional changes
• Reduces reliance on systemic opioids by directly altering nociceptive transmission

Peripheral Nerve Stimulation for Localized Syndromes

Peripheral Nerve Stimulation (PNS) for localized syndromes precisely targets a single accessible nerve supplying a specific painful region, such as the ulnar, tibial, or occipital nerve. Unlike spinal cord stimulation, it avoids paresthesia coverage of large dermatomes, instead placing a lead percutaneously near the target nerve to modulate afferent nociceptive signals. This technique is particularly effective for mononeuropathies and focal post-surgical pain where pathology is anatomically confined, offering a site-specific neuromodulation strategy that preserves sensory function outside the stimulated territory. Clinical utility hinges on accurate nerve localization via ultrasound or stimulation mapping, and programming prioritizes low-amplitude, distal-paresthesia coverage to maximize therapeutic benefit while minimizing motor recruitment.

Transcutaneous Electrical Nerve Stimulation in Home Care

Transcutaneous Electrical Nerve Stimulation (TENS) in home care empowers patients to self-manage chronic pain by placing electrode pads on specific skin areas to deliver low-voltage electrical pulses. This non-invasive therapy interrupts pain signals traveling to the brain, offering immediate relief for conditions like lower back or arthritic pain without medication. Device settings must be carefully adjusted to avoid habituation, as the body’s response diminishes with constant patterns. Users typically operate compact, battery-powered units for 30-minute sessions multiple times daily, with modern models offering programmable pulse rates to target dull or sharp sensations.

• Pads require proper skin cleaning and gel application to maintain conductivity
• Placement must target dermatomes or trigger points for effective nerve pathway disruption
• Start with low intensity, increasing gradually until a strong but comfortable tingling is felt

Deep Brain and Motor Cortex Stimulation for Refractory Cases

For refractory cases unresponsive to conventional neuromodulation, deep brain stimulation (DBS) targets the periaqueductal gray or thalamus to disrupt pathological pain circuits, while motor cortex stimulation (MCS) is applied epidurally over the precentral gyrus for central post-stroke or trigeminal neuropathic pain. Both procedures require stereotactic or frameless navigation for precise lead placement, with intraoperative testing guiding parameter optimization. Motor cortex stimulation for central pain shows a roughly 50-70% responder rate in carefully selected patients, though efficacy often diminishes over months, necessitating repeated programming adjustments. DBS carries a higher surgical risk due to subcortical target access, including hemorrhage and infection, making patient candidacy rigorous.

• DBS targets periaqueductal gray or ventral posterolateral thalamus for nociceptive or deafferentation pain syndromes.
• MCS uses a paddle or cylindrical lead over the motor cortex, typically requiring somatosensory evoked potential mapping for placement.
• Stimulation parameters for DBS range from 30–130 Hz with pulse widths of 60–210 µs, while MCS uses 20–50 Hz with 90–210 µs pulses.
• Both modalities require a trial phase (7–14 days) before permanent implantation to confirm at least 50% pain reduction.

Patient Selection Criteria for Optimal Outcomes

For optimal outcomes with neurostimulation for chronic pain management, patient selection criteria hinge on a confirmed diagnosis like failed back surgery syndrome or complex regional pain syndrome. Candidates should have failed conservative treatments and show no untreated coagulopathy or active infection. A crucial step is a successful trial, which requires at least 50% pain relief during the temporary stimulation period. Psychological readiness is key: patients must be free from significant untreated depression or somatization, as these factors greatly reduce device efficacy. A clear understanding of realistic results—that neurostimulation often dulls pain rather than erasing it—is non-negotiable for long-term satisfaction.

Identifying Candidates With Failed Conservative Therapies

The primary criterion for neurostimulation candidacy is documented failure of conservative therapies, defined as inadequate pain relief or intolerable side effects after a structured, multi-modal regimen of at least 3-6 months. This includes physical therapy, oral analgesics, and interventional procedures. Clinicians must verify adherence and objective non-response through patient diaries and functional assessments, not just subjective reports. Failed conservative therapy is a prerequisite, not a diagnostic endpoint, requiring exclusion of psychogenic contributors or untreated structural pathology.

• Confirm trial of at least three distinct conservative modalities (e.g., PT, NSAIDs, nerve blocks) with documented duration and dosing.
• Assess objective functional decline (e.g., reduced walking distance, sleep disruption) despite treatment adherence.
• Rule out untreated red flags (e.g., infection, malignancy, instability) that would contraindicate neurostimulation.

Psychological Assessments and Realistic Expectations

Psychological assessments identify factors like mood disorders, catastrophizing, or poor coping that predict suboptimal neurostimulation outcomes. Realistic expectation setting then directly modulates trial success by aligning patient hopes with typical pain reduction (often 50–60%) and functional gains, not cure. The assessment process follows a clear sequence:

1. Screen for untreated depression or anxiety that undermines device engagement.
2. Evaluate pain beliefs to correct misconceptions about total relief.
3. Discuss specific post-implant lifestyle adjustments, such as reduced reliance on opioids.

Even a psychometrically sound evaluation cannot guarantee adherence if goals remain mismatched to device capabilities. Thus, pre-implant counseling explicitly links psychological readiness to realistic, incremental milestones—avoiding disappointment that leads to explant.

Contraindications Related to Comorbidities and Implants

Patient selection for neurostimulation requires rigorous evaluation of comorbidity-driven contraindications. Uncontrolled coagulopathy or active anticoagulation raises bleeding risk during lead placement. Severe cardiopulmonary disease (e.g., unstable angina) may preclude the prone positioning or anesthesia needed for implantation. For patients with implanted cardiac devices (pacemakers, defibrillators), magnetic resonance imaging (MRI) compatibility and electromagnetic interference must be assessed, as some neurostimulators are MRI-conditional only. Spinal implants, such as pedicle screws or fusion rods, can distort current flow, reducing therapeutic efficacy or causing unwanted stimulation. Active infection at the implantation site or systemic immunosuppression is an absolute contraindication due to sepsis risk.

Implantation Procedures and Technological Innovations

Modern implantation procedures for neurostimulation in chronic pain management have evolved toward minimally invasive, percutaneous lead placement under fluoroscopic guidance, often performed as outpatient procedures. Technological innovations include smaller, rechargeable implantable pulse generators that reduce surgical pocket size and extend device longevity. A critical advancement is the integration of closed-loop or evoked compound action potential (ECAP) sensing, which dynamically adjusts stimulation parameters based on real-time neural response, improving therapeutic consistency. For optimal lead anchoring, practitioners should consider ultrasound-guided fascial fixation to minimize migration, a technique that reduces revision rates significantly. These developments collectively enhance procedural safety, target specificity, and patient stimulation comfort.

Minimally Invasive Lead Placement Techniques

Percutaneous lead placement is the core of minimally invasive techniques, using a Tuohy needle to thread cylindrical leads into the epidural space under fluoroscopic guidance, often targeting the dorsal column. The procedure avoids the muscle dissection and laminotomy required for paddle leads, reducing tissue trauma and recovery time. Leads are positioned via loss-of-resistance to air or saline, with real-time paresthesia mapping confirming coverage of the painful dermatome. Anchoring at the supraspinous ligament minimizes migration risk. Biphasic waveforms are programmed postoperatively, and patients undergo a trial period before permanent implantation, leveraging small incisions for ambulatory discharge within hours.

• Temporary trial lead placement enables patient feedback before permanent implantation, ensuring effective paresthesia coverage.
• Single or dual octrode leads are advanced via a single skin entry point, allowing multicolumn coverage with minimal incisions.
• Microelectrode recording is omitted, focusing solely on anatomical targeting through lateral and anterior-posterior fluoroscopic views.

Rechargeable vs. Non-Rechargeable Battery Systems

For neurostimulation in chronic pain, the choice between rechargeable and non-rechargeable battery systems directly impacts long-term patient convenience. A rechargeable system, requiring weekly charging via an external charger, offers a longer device lifespan (typically 9–10 years) and is ideal for high-energy, multi-lead stimulators. Conversely, a non-rechargeable system eliminates patient charging duties entirely, providing simplicity at the cost of a shorter battery life (3–5 years) and mandatory surgical replacement. Practical selection hinges on the patient’s willingness to manage charging versus their tolerance for repeat procedures.

• Rechargeable systems demand consistent patient compliance with weekly charging schedules.
• Non-rechargeable systems require replacement surgery every few years for depleted batteries.
• Rechargeable batteries support more sophisticated stimulation programs without sacrificing longevity.
• Non-rechargeable systems offer a simpler, maintenance-free experience for less complex pain conditions.

Closed-Loop Systems That Adapt to Nerve Activity

Closed-loop systems represent a technological leap in neurostimulation by continuously monitoring neural signals and adjusting stimulation parameters in real-time. Unlike open-loop devices, these implants analyze evoked compound action potentials or local field potentials to deliver adaptive pain relief that mirrors fluctuating nerve activity. This dynamic feedback mechanism minimizes overstimulation and battery drain, as the system activates or modifies output only when neural signatures of pain are detected. For instance, real-time calibration can prevent the paresthesia habituation common in traditional spinal cord stimulators. Q: How does a closed-loop system differentiate between pain signals and normal nerve traffic? A: It uses machine-learning algorithms trained on baseline neural patterns; the device learns to filter routine activity and responds only to aberrant patterns linked to chronic pain, ensuring precise intervention without constant stimulation.

MRI-Conditional Devices and Safety Considerations

MRI-conditional neurostimulation devices are designed to operate safely within a defined magnetic resonance environment, provided strict guidelines are followed. For chronic pain patients, this means scanning is permissible only under specified conditions, such as a limited field strength (typically 1.5 or 3 Tesla) and restricted specific absorption rate (SAR) levels. You must confirm lead configurations and anatomical placement pre-scan, as improper positioning can cause heating or induced currents at the electrode-tissue interface. Always verify the device’s specific model parameters and scan region—only fully documented, labeled systems allow safe imaging. Device programmers must deactivate stimulation before entering the MRI room, and post-scan functionality checks are non-negotiable. Adhering to these protocols eliminates risks of tissue damage or device malfunction during essential diagnostic imaging.

Programming Strategies to Maximize Relief

Programming strategies to maximize relief in neurostimulation for chronic pain management focus on precisely matching stimulation parameters to the patient’s unique paresthesia coverage. Clinicians must leverage sub-perception programming, using high-frequency or burst waveforms to deliver analgesia without undesirable tingling. The most effective approach involves iterative field shaping, adjusting electrode configuration and amplitude across multiple contacts to fully overlap the patient’s specific pain map. Active patient feedback during programming is critical; you must titrate pulse width and rate in real-time to capture variable pain distributions. Prioritizing closed-loop or adaptive algorithms that automatically adjust output based on posture ensures sustained relief during movement, preventing breakthrough pain. This targeted, interactive methodology consistently outperforms static, one-size-fits-all settings in achieving durable, personalized outcomes.

Trial Periods and Customized Parameter Adjustments

During neurostimulation for chronic pain, the trial period remains critical for customized parameter adjustments. Patients typically undergo a temporary implant for up to seven days, during which clinicians iteratively modify amplitude, pulse width, and frequency. This live titration evaluates paresthesia coverage and pain reduction without permanent placement. Adjustments are often guided by real-time patient feedback on specific activities like walking or sleeping. Parameter sets are then locked for the implanted system, ensuring the therapy targets the individual’s neuropathic pain profile precisely.

Trial periods enable patient-specific parameter optimization, confirming effective neurostimulation before permanent implantation through iterative amplitude, pulse width, and frequency adjustments.

Frequency, Pulse Width, and Amplitude Optimization

Optimizing frequency, pulse width, and amplitude is critical for targeting specific pain pathways without causing uncomfortable side effects. Lower frequencies (10–50 Hz) typically recruit motor fibers for a massaging sensation, while higher frequencies (100–1000 Hz) target sensory fibers to block sharp pain. Pulse width adjustments—narrower (60–120 µs) for superficial nerves, wider (200–400 µs) for deeper structures—refine the electrical field’s penetration. Amplitude must be titrated carefully to remain below motor threshold yet above paresthesia threshold for effective coverage. **Q: How do you balance frequency and amplitude to avoid muscle twitching?** A: Start with a mid-range frequency (e.g., 50 Hz) while slowly increasing amplitude until you feel a comfortable tingling, then fine-tune pulse width to localize the sensation precisely over the thync pain area.

Burst and High-Density Stimulation Patterns

Burst and High-Density Stimulation Patterns offer distinct mechanisms for maximizing relief. Burst stimulation delivers packets of five high-frequency pulses, mimicking natural firing patterns to potentially reduce paresthesia-free pain suppression. High-Density Stimulation increases pulse frequency (e.g., 1,000 Hz) within standard parameters, providing greater charge delivery per second. Clinicians often reserve burst for patients who rebuff traditional tonic stimulation due to uncomfortable sensations. While burst targets central pain pathways through non-paresthetic effects, high-density focuses on augmenting peripheral nerve blockade. Burst therapy may improve sleep quality, whereas high-density excels in dynamic pain scenarios. A patient’s response to one pattern does not predict efficacy of the other, demanding systematic trial.

Evidence-Based Efficacy and Long-Term Results

Randomized controlled trials demonstrate that neurostimulation for chronic pain achieves ≥50% pain relief in over 60% of patients with failed back surgery syndrome, a benchmark rarely met by conservative therapies. Long-term registry data confirm that these analgesic effects remain stable for at least 24 months, with responders maintaining reduced opioid use and improved function. Evidence supports sustained spinal cord stimulation efficacy for neuropathic limb pain, while dorsal root ganglion stimulation shows superior results for focal pain syndromes like complex regional pain syndrome. Long-term lead migration remains the primary failure cause, yet modern percutaneous leads exhibit less than 5% reoperation rates at five years. The durability of outcomes hinges critically on meticulous patient selection and a trial period, not simply implantation technique. Systematic reviews now classify neurostimulation as a Level I evidence treatment for chronic back and leg pain.

Comparative Studies Against Conventional Treatments

Comparative studies against conventional treatments demonstrate that neurostimulation often yields superior long-term pain reduction for specific chronic conditions. Randomized trials show spinal cord stimulation provides greater efficacy than reoperation or medication management for failed back surgery syndrome, with sustained benefit at 24 months. A clear sequence emerges from the evidence:

1. Patients failing conservative care receive neurostimulation as a validated alternative to long-term opioid therapy, with lower systemic side effects.
2. Comparative data confirm neurostimulation reduces pain scores by 50-70% versus 30-40% for conventional physical therapy in diabetic neuropathy.
3. Head-to-head analysis indicates fewer adverse events and higher patient satisfaction compared to repeat surgical interventions.

This positions neurostimulation as a direct comparative upgrade for appropriately selected patients.

Success Rates for Diabetic Neuropathy and Failed Back Surgery

Success rates for neurostimulation in treating painful diabetic neuropathy (PDN) show that approximately 60-75% of patients achieve at least 50% pain relief at 12 months. For failed back surgery syndrome (FBSS), long-term results indicate a 50-60% success rate in sustained pain reduction over 5-24 months. Differential success rates by condition emerge, as PDN patients often report faster functional improvement, while FBSS outcomes depend heavily on electrode placement and patient selection. A clear sequence includes:

1. Patient trials for both conditions to identify responders.
2. Permanent implant for those achieving ≥50% pain relief.
3. Ongoing programming adjustments to maintain success, with higher long-term adherence in PDN than in FBSS patients.

Complication Rates and Common Adverse Events

When it comes to neurostimulation, complication rates are generally low but worth knowing. The most common adverse events include lead migration, infection at the implant site, and hardware malfunctions like battery failure. Lead migration is a frequent complication, sometimes requiring surgical revision if stimulation loses its targeted effect. You might also experience temporary pain or tingling at the generator pocket. Most adverse events are mild and resolve with reprogramming or minor adjustments, rather than full removal. Q: How often do these complications lead to permanent issues? A: Serious permanent problems are rare—less than 5% of cases, with infection being the main risk if not caught early.

Emerging Directions and Future Horizons

Emerging directions in neurostimulation are moving toward closed-loop systems that adapt stimulation in real-time based on neural feedback, offering dynamic pain relief that mirrors natural physiology. Future horizons include the integration of high-resolution, patterned stimulation to target specific spinal or brain circuits, potentially reducing habituation. Advances in minimally invasive electrode placement and non-invasive transcranial modalities promise broader patient access. These technologies aim to personalize therapy by learning individual pain signatures, shifting management from static blocks to an evolving, responsive partnership between device and user. The ultimate horizon is a seamless, adaptive system that preempts pain flares before they register.

Non-Invasive Wearables for Chronic Ailments

Non-invasive wearables for chronic ailments now enable patients to manage neuropathic pain through transcutaneous electrical nerve stimulation units worn like smartwatches or patches. These devices deliver precise, user-controlled impulses to peripheral nerves, bypassing the need for implanted electrodes. Closed-loop wearables adjust stimulation intensity in real-time based on biosignals like skin conductance, preventing overstimulation. They learn individual pain thresholds over weeks, offering personalized relief without daily medication. How do these wearables differ from standard TENS units? They integrate motion and heart-rate sensors to synchronize pulses with activity levels, so walking or sleeping doesn’t trigger false pain spikes.

Combination Therapies With Physical Rehabilitation

Combination therapies integrate neurostimulation with physical rehabilitation to address the neuroplastic changes reinforcing chronic pain. By pairing spinal cord stimulation with targeted motor retraining, clinicians can first reduce pain-driven inhibition, then leverage rehabilitation to rebuild proper movement patterns. This synergy prevents the brain from reverting to maladaptive motor strategies. A key mechanism is activity-dependent sensory retraining, where stimulation gates aberrant pain signals while rehabilitation exercises guide the central nervous system toward normal sensorimotor integration. The two modalities operate in a closed loop: neurostimulation creates a window of reduced pain intensity, enabling higher-quality rehab, and the rehab reinforces the cortical desensitization initiated by the stimulation.

Machine Learning Algorithms for Automated Adjustments

Machine learning algorithms enable closed-loop neurostimulation systems to autonomously adjust stimulation parameters in real-time based on incoming biometric data. These models analyze patterns in neural signals or peripheral biomarkers to predict pain fluctuations and modulate output frequency or amplitude without patient intervention. Reinforcement learning algorithms are frequently employed, allowing the device to optimize settings through iterative feedback from pain scores and movement data. This reduces the need for manual reprogramming and adapts to diurnal or activity-related changes. Automated adaptive stimulation thus improves consistency of pain relief while minimizing paresthesia or side effects.

Machine learning algorithms for automated adjustments allow neurostimulators to self-optimize by learning from patient-specific physiological responses, delivering personalized modulation without manual input.

Gene Therapy and Optogenetic Alternatives on the Horizon

Gene therapy for chronic pain targets ion channel overexpression, such as NaV1.7, to durably silence nociceptors without daily stimulation. Optogenetic alternatives use light-sensitive opsins like channelrhodopsin to activate or inhibit specific neural circuits with millisecond precision, offering an alternative to electrode-based neurostimulation. Both approaches are progressing through preclinical trials, aiming to provide long-lasting, cell-type-specific pain control. Optogenetic alternatives require external light delivery via implanted fiber optics or viral vector expression, while gene therapy may employ CRISPR-based editing for sustained effect. These horizons could eventually replace conventional spinal cord stimulators with biological, circuit-targeted solutions.

Gene therapy and optogenetic alternatives represent emerging biological strategies to replace or augment traditional neurostimulation, offering durable, cell-specific pain modulation through viral vector and light-sensitive protein technologies.

What This Nerve-Based Approach Does Differently for Lasting Relief

How electrical signals override pain messages before they reach the brain

Key differences between spinal cord stimulation and peripheral nerve stimulation

Who Benefits Most From This Pain Intervention

Conditions where electrical modulation shows the strongest response

Signs you might be a good candidate versus when to consider alternatives

How the Implanted System Actually Works Day to Day

What happens during the trial period before a permanent device

Adjusting stimulation settings to match your specific pain patterns

Practical Benefits You Can Expect After Setup

Reducing reliance on oral medications and their side effects

Improving sleep quality and daily physical function

Choosing Between Device Types and Placement Options

Rechargeable versus non-rechargeable power sources

Targeting different body areas: back, limbs, or specific nerve paths

Common User Questions About Living With the System

Can you still undergo MRI scans after implantation

What sensations are normal during active stimulation